Enovis Corporation (ENOV) Stock
Key stats
- Market cap
- $1.65B
- Price / Earnings ratio
- -3.1x
- EPS (TTM)
- -$9.22
- Volume
- Loading
- 52-week high
- $32.41
- 52-week low
- $16.70
Source: third-party data provider, as of November 13, 2026
Compare with ENOV
Recent news

Insider at Medical Device Maker Buys More Than 7,500 Shares
Insider at Medical Device Maker Buys More Than 7,500 Shares
ENOV

What Makes Enovis (ENOV) a New Buy Stock
What Makes Enovis (ENOV) a New Buy Stock
ENOV

Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ENOV

Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition
ENOV
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 71.11
- MACD 12/26/9
- 2.21
- EMA 9 of MACD
- 1.41
- MACD histogram
- 0.80
- SMA 50
- $20.21
- Price above SMA 50
- EMA 50
- $22.15
- Price above EMA 50
- SMA 200
- $23.18
- Price above SMA 200
- EMA 200
- $23.18
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Insider at Medical Device Maker Buys More Than 7,500 Shares
Insider at Medical Device Maker Buys More Than 7,500 Shares
ENOV

What Makes Enovis (ENOV) a New Buy Stock
What Makes Enovis (ENOV) a New Buy Stock
ENOV

Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ENOV

Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition
ENOV

Enovis Targets Robotic Surgery Expansion With €155M eCential Robotics Deal
Enovis Targets Robotic Surgery Expansion With €155M eCential Robotics Deal
ENOV

Enovis Q2 Earnings Call Highlights
Enovis Q2 Earnings Call Highlights
ENOV

Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates
Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates
ENOV

Does Enovis (ENOV) Have the Potential to Rally 65.45% as Wall Street Analysts Expect?
Does Enovis (ENOV) Have the Potential to Rally 65.45% as Wall Street Analysts Expect?
ENOV

Enovis Q1 Earnings Call Highlights
Enovis Q1 Earnings Call Highlights
ENOV

Enovis (ENOV) Q1 Earnings and Revenues Beat Estimates
Enovis (ENOV) Q1 Earnings and Revenues Beat Estimates
ENOV
News tone: automated (AI) classification of the article's content, not a price prediction.
About Enovis Corporation
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Damien McDonald | CEO & Director | 1965 |
| Mr. Phillip Benjamin Berry | Senior VP & CFO | 1979 |
| Ms. Patricia A. Lang | Advisor | 1959 |
| Mr. Terry D. Ross | Group President Prevention & Recovery | 1970 |
| Mr. Louie Vogt | Group President of Reconstructive | 1981 |
| Mr. John Kleckner | VP, Controller & Chief Accounting Officer | 1977 |
| Mr. Oliver Engert | Chief Administrative Officer | 1965 |
| Mr. Kyle William Rose | Vice President of Investor Relations | — |
| Mr. Bradley J. Tandy J.D. | Senior VP & Chief Legal Officer | 1959 |
| Ms. Laura Singleton | Senior VP & Chief Human Resources Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 71.11
- MACD 12/26/9
- 2.21
- EMA 9 of MACD
- 1.41
- MACD histogram
- 0.80
- SMA 50
- $20.21
- Price above SMA 50
- EMA 50
- $22.15
- Price above EMA 50
- SMA 200
- $23.18
- Price above SMA 200
- EMA 200
- $23.18
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $33.00
- Average
- $39.29
- High
- $47.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | -7.9 | +1.9 | -17.6 | +6.6 | -15.1 | -7.1 | +4.0 | +9.2 | -5.3 | |||
| 2023 | +15.7 | -10.6 | -6.7 | +8.9 | -10.2 | +19.2 | +1.1 | -12.1 | -6.7 | -10.3 | +9.8 | +9.9 |
| 2024 | +5.9 | +0.3 | +3.4 | -10.1 | -9.3 | -8.1 | +7.4 | +0.1 | -3.4 | -0.5 | +15.0 | -11.0 |
| 2025 | +6.0 | -14.6 | +0.9 | -7.0 | -9.5 | +5.8 | -18.8 | +20.0 | -1.6 | +2.6 | -3.5 | -9.3 |
| 2026 | -16.9 | +14.9 | -11.5 | +0.3 | -4.0 | -4.6 | +45.5 | -21.7 | -11.0 | +10.3 | +38.5 |



